Acadian Asset Management LLC 89bio, Inc. Transaction History

Acadian Asset Management LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$5.52 - $12.73 $393,266 - $906,936	-71,244 Reduced 57.87%	51,861 $660,000
Q3 2022 Nov 14, 2022	BUY	$3.02 - $7.0 $53,396 - $123,767	17,681 Added 16.77%	123,105 $712,000
Q2 2022 Aug 09, 2022	BUY	$2.09 - $4.02 $200,991 - $386,595	96,168 Added 1038.98%	105,424 $340,000
Q1 2022 May 12, 2022	BUY	$3.45 - $14.99 $31,933 - $138,747	9,256 New	9,256 $34,000

175

125M

84K

941K

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $491M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Acadian Asset Management LLC with notifications on news.